Paralysis: Clinical Trials

11 trials for Paralysis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 terminated. 11 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Terminated 11
Phase 23Terminated 3

Follow Paralysis: new trials by email Literature Review of Paralysis trials Research Report on Paralysis

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident
Phase 2 / Phase 3TerminatedSolstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC322021-11-022026-05-27
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity
Phase 2 / Phase 3TerminatedSolstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC402019-12-172026-05-22
Diabetic Gastroparesis Study 05
Relamorelin 10 μg - Gastroparesis
Phase 3TerminatedAllergan2022018-12-202021-12-15
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus
Phase 3TerminatedAllergan3112018-02-162021-08-06
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus
Phase 3TerminatedAllergan4502018-02-012021-11-23
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus
Phase 3TerminatedAllergan4672018-01-242021-12-22
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus
Phase 3TerminatedAllergan3362017-09-292021-07-29
Effects of the Quantity of Repetitive Transcranial Magnetic Stimulation(rTMS) on the Recovery After Stroke
repetitive transcranial magnetic stimulation (rTMS) - Stroke, Hemiplegia
Phase 2 / Phase 3TerminatedSeoul National University Bundang Hospital22011-01-012015-05-19
Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
Rasagiline, Sugar pill - Progressive Supranuclear Palsy
Phase 3TerminatedProf. Dr. Stefan Lorenzl442010-01-012013-04-24
Surgery for Vocal Cord Paralysis
vocal fold medialization, vocal fold reinnervation - Unilateral Vocal Cord Paralysis
Phase 3TerminatedNational Institute on Deafness and Other Communication Disorders (NIDCD)3002002-10-012006-04-24
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
Riluzole - Multiple System Atrophy, Progressive Supranuclear Palsy
Phase 3TerminatedKing's College London8002000-04-012005-12-15

Narrower conditions

Gastroparesis (5)  ·  Diabetes Mellitus (4)  ·  Hemiplegia (3)  ·  Stroke (3)  ·  Brain Injuries, Traumatic (2)  ·  Muscle Spasticity (2)  ·  Supranuclear Palsy, Progressive (2)  ·  Vomiting (2)  ·  Cerebral Palsy (1)  ·  Cerebrovascular Disorders (1)  ·  Multiple Sclerosis (1)  ·  Multiple System Atrophy (1)  ·  Vocal Cord Paralysis (1)

Broader conditions

Neurologic Manifestations (11)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Signs and Symptoms (11)  ·  Nervous System Diseases (6)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Digestive System Diseases (5)  ·  Gastrointestinal Diseases (5)  ·  Stomach Diseases (5)  ·  Endocrine System Diseases (4)  ·  Glucose Metabolism Disorders (4)  ·  Metabolic Diseases (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Cardiovascular Diseases (3)

Interventions

relamorelin (5)  ·  Clinical Trials, Phase II as Topic (2)  ·  Clinical Trials, Phase III as Topic (2)  ·  rimabotulinumtoxinB (2)  ·  Riluzole (1)  ·  Sugars (1)  ·  Transcranial Magnetic Stimulation (1)  ·  rasagiline (1)

Sponsors

Allergan (5)  ·  Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2)  ·  King's College London (1)  ·  National Institute on Deafness and Other Communication Disorders (NIDCD) (1)  ·  Prof. Dr. Stefan Lorenzl (1)  ·  Seoul National University Bundang Hospital (1)

Countries

United States (8)  ·  Hungary (6)  ·  Poland (6)  ·  Germany (5)  ·  South Korea (5)  ·  United Kingdom (5)  ·  Argentina (4)  ·  Australia (4)  ·  Austria (4)  ·  Belgium (4)  ·  Brazil (4)  ·  Bulgaria (4)  ·  Canada (4)  ·  Colombia (4)  ·  Denmark (4)

Top investigators

Harvy Schneier (2)  ·  Joseph T Hull, PhD (2)  ·  Nam-Jong Paik, MD, PhD (1)  ·  Peter N Leigh, PhD FRCP (1)  ·  Randal C Paniello, MD (1)  ·  Stefan Lorenzl, PD Dr. (1)  ·  Wieslaw Bochenek (1)

Results publications

PMID 19029129, PMID 19771175, PMID 21386111, PMID 21829612, PMID 40148033

NIH funding

2017 (3), 2008 (1), 2019 (1)